

DAFTAR PUSTAKA

- Ae-Ngibise, K. A. *et al.* (2019) 'Prenatal maternal stress and birth outcomes in rural Ghana: Sex-specific associations', *BMC Pregnancy and Childbirth*, 19(1), pp. 1–8. doi: 10.1186/s12884-019-2535-9.
- Afzal, A., Hussain, T. and Hameed, A. (2021) 'Moringa oleifera Supplementation Improves Antioxidant Status and Biochemical Indices by Attenuating Early Pregnancy Stress in Beetal Goats', *Frontiers in Nutrition*, 8(July), pp. 1–13. doi: 10.3389/fnut.2021.700957.
- Al-Gubory, K. H. (2014) 'Environmental pollutants and lifestyle factors induce oxidative stress and poor prenatal development', *Reproductive BioMedicine Online*, 29(1), pp. 17–31. doi: 10.1016/j.rbmo.2014.03.002.
- Al-Gubory, K. H. (2016) 'Multiple exposures to environmental pollutants and oxidative stress: Is there a sex specific risk of developmental complications for fetuses?', *Birth Defects Research Part C - Embryo Today: Reviews*, 108(4), pp. 351–364. doi: 10.1002/bdrc.21142.
- Al-Gubory, K. H., Fowler, P. A. and Garrel, C. (2010) 'The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes', *International Journal of Biochemistry and Cell Biology*, 42(10), pp. 1634–1650. doi: 10.1016/j.biocel.2010.06.001.
- Alegbeleye, O. O. (2018) 'How Functional Is Moringa oleifera? A Review of Its Nutritive, Medicinal, and Socioeconomic Potential', *Food and Nutrition Bulletin*, 39(1), pp. 149–170. doi: 10.1177/0379572117749814.
- Anggraeni, S., Setyaningrum, T. and Listiawan, Y. (2017) 'Perbedaan Kadar Malondialdehid (MDA) sebagai Petanda Stres Oksidatif pada Berbagai Derajat Akne Vulgaris', *Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of Dermatology and Venereology*, 29(1), pp. 36–43.
- Atrash, H. and Jack, B. (2020) 'Preconception Care to Improve Pregnancy Outcomes: The Science', *Journal of Human Growth and Development*, 30(3), pp. 355–362. doi: 10.7322/jhgd.v30.11064.
- Baldisserotto, A. *et al.* (2018) 'Moringa oleifera leaf extracts as multifunctional ingredients for "natural and organic" sunscreens and photoprotective preparations', *Molecules*, 23(3). doi: 10.3390/molecules23030664.

- Basri, H. *et al.* (2021) 'Effect of moringa oleifera supplementation during pregnancy on the prevention of stunted growth in children between the ages of 36 to 42 months', *Journal of Public Health Research*, 10(2), pp. 290–295. doi: 10.4081/jphr.2021.2207.
- Basri, H. *et al.* (2022) 'Effect of Moringa Oliefera Supplementation During Pregnancy on Nutritional Status in Children 2–5 Years Old in Indonesia: A-Follow-Up Study', *Current Developments in Nutrition*, 6(Supplement_1), pp. 885–885. doi: 10.1093/cdn/nzac067.005.
- Birben, E. *et al.* (2012) 'Oxidative stress and antioxidant defense', *World Allergy Organization Journal*, 5(1), pp. 9–19. doi: 10.1097/WOX.0b013e3182439613.
- Bolten, M. I. *et al.* (2011) 'Cortisol levels in pregnancy as a psychobiological predictor for birth weight', *Archives of Women's Mental Health*, 14(1), pp. 33–41. doi: 10.1007/s00737-010-0183-1.
- Brilhante, R. S. N. *et al.* (2017) 'Research advances on the multiple uses of Moringa oleifera: A sustainable alternative for socially neglected population', *Asian Pacific Journal of Tropical Medicine*, 10(7), pp. 621–630. doi: 10.1016/j.apjtm.2017.07.002.
- van den Broek, N. *et al.* (2002) 'Vitamin A supplementation during pregnancy', *Cochrane Database of Systematic Reviews*, (4). doi: 10.1002/14651858.cd001996.
- Bukowski, R. *et al.* (2009) 'Preconceptional folate supplementation and the risk of spontaneous preterm birth: A cohort study', *PLoS Medicine*, 6(5). doi: 10.1371/journal.pmed.1000061.
- Catov, J. M. *et al.* (2011) 'Periconceptional multivitamin use and risk of preterm or small-for-gestational-age Births in the Danish National birth cohort', *American Journal of Clinical Nutrition*, 94(3), pp. 906–912. doi: 10.3945/ajcn.111.012393.
- Cetin, I., Berti, C. and Calabrese, S. (2010) 'Role of micronutrients in the periconceptional period', 16(1), pp. 80–95. doi: 10.1093/humupd/dmp025.
- Cheenpracha, S. *et al.* (2010) 'Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits', *Bioorganic and Medicinal Chemistry*, 18(17), pp. 6598–6602. doi: 10.1016/j.bmc.2010.03.057.
- Cheng, Y. C. *et al.* (2017) 'Polyphenols and Oxidative Stress in Atherosclerosis-Related Ischemic Heart Disease and Stroke',

Oxidative Medicine and Cellular Longevity, 2017. doi: 10.1155/2017/8526438.

- Chiarello, D. I. *et al.* (2020) *Oxidative stress: Normal pregnancy versus preeclampsia*, *Biochimica et Biophysica Acta - Molecular Basis of Disease*. Elsevier B.V. doi: 10.1016/j.bbadis.2018.12.005.
- Cinkaya, A. *et al.* (2010) 'Maternal plasma total antioxidant status in preterm labor', *Journal of Obstetrics and Gynaecology Research*, 36(6), pp. 1185–1188. doi: 10.1111/j.1447-0756.2010.01300.x.
- Coussons-Read, M. E. (2013) 'Effects of prenatal stress on pregnancy and human development: Mechanisms and pathways', *Obstetric Medicine*, 6(2), pp. 52–57. doi: 10.1177/1753495X12473751.
- Cuffe, J. S., Xu, Z. C. and Perkins, A. V. (2017) 'Biomarkers of oxidative stress in pregnancy complications', *Biomarkers in Medicine*, 11(3), pp. 295–306. doi: 10.2217/bmm-2016-0250.
- Czeizel, A. E. (1993) 'Prevention of congenital abnormalities by periconceptional multivitamin supplementation', *British Medical Journal*, 306(6893), pp. 1645–1648. doi: 10.1136/bmj.306.6893.1645.
- Davis, E. P. *et al.* (2011) 'Prenatal maternal stress programs infant stress regulation', *Journal of Child Psychology and Psychiatry and Allied Disciplines*, 52(2), pp. 119–129. doi: 10.1111/j.1469-7610.2010.02314.x.
- Dean, S. V. *et al.* (2014) 'Preconception care: Nutritional risks and interventions', *Reproductive Health*, 11(Suppl 3), pp. 1–15. doi: 10.1186/1742-4755-11-S3-S3.
- DelvicaSahertian, V. H., WernaNontji, A. N. and ... (2021) 'The Impact of Moringa Honey on Pregnant Women's Nutrient Intake and Malondialdehyde (MDA) Levels in Maros Regency', *Turkish Journal of ...*, 12(14), pp. 2669–2676. Available at: <https://turcomat.org/index.php/turkbilmat/article/download/10688/8011>.
- Dhaded, S. M. *et al.* (2020) 'Preconception nutrition intervention improved birth length and reduced stunting and wasting in newborns in South Asia: The Women First Randomized Controlled Trial', *PLoS ONE*, 15(1), pp. 1–15. doi: 10.1371/journal.pone.0218960.
- Dsouza, V. *et al.* (2016) 'Increased oxidative stress from early pregnancy in women who develop preeclampsia', *Clinical and Experimental*

- Hypertension*, 38(2), pp. 225–232. doi: 10.3109/10641963.2015.1081226.
- Duhig, K., Chappell, L. C. and Shennan, A. H. (2016) 'Oxidative stress in pregnancy and reproduction', *Obstetric Medicine*, 9(3), pp. 113–116. doi: 10.1177/1753495X16648495.
- Duthie, L. and Reynolds, R. M. (2013) 'Changes in the maternal hypothalamic-pituitary-adrenal axis in pregnancy and postpartum: Influences on maternal and fetal outcomes', *Neuroendocrinology*, 98(2), pp. 106–115. doi: 10.1159/000354702.
- Eberle, C. *et al.* (2021) 'Impact of maternal prenatal stress by glucocorticoids on metabolic and cardiovascular outcomes in their offspring: A systematic scoping review', *PLoS ONE*, 16(1 January), pp. 1–14. doi: 10.1371/journal.pone.0245386.
- Egliston, K. A., McMahon, C. and Austin, M. P. (2007) 'Stress in pregnancy and infant HPA axis function: Conceptual and methodological issues relating to the use of salivary cortisol as an outcome measure', *Psychoneuroendocrinology*, 32(1), pp. 1–13. doi: 10.1016/j.psyneuen.2006.10.003.
- Engidaw, N. A., Mekonnen, A. G. and Amogne, F. K. (2019) 'Perceived stress and its associated factors among pregnant women in Bale zone Hospitals, Southeast Ethiopia: A cross-sectional study', *BMC Research Notes*, 12(1), pp. 1–6. doi: 10.1186/s13104-019-4383-0.
- Fan, F. *et al.* (2018) 'The relationship between maternal anxiety and cortisol during pregnancy and birth weight of chinese neonates', *BMC Pregnancy and Childbirth*, 18(1), pp. 1–6. doi: 10.1186/s12884-018-1798-x.
- Fenech, M. (2011) 'Micronuclei and their association with sperm abnormalities, infertility, pregnancy loss, pre-eclampsia and intra-uterine growth restriction in humans', *Mutagenesis*, 26(1), pp. 63–67. doi: 10.1093/mutage/geq084.
- Ferrari, F. *et al.* (2016) 'Placental telomere shortening in stillbirth: A sign of premature senescence?', *Journal of Maternal-Fetal and Neonatal Medicine*, 29(8), pp. 1283–1288. doi: 10.3109/14767058.2015.1046045.
- Fitri Kumalasary, V. H. *et al.* (2021) 'The Effect of Giving Moringa Honey on Stress and Cortisol Levels in Pregnant Women in Maros Regency', *Turkish Journal of ...*, 12(14), pp. 2669–2676.

- Gardiner, P. M. *et al.* (2008) 'The clinical content of preconception care: nutrition and dietary supplements', *American Journal of Obstetrics and Gynecology*, 199(6 SUPPL. B). doi: 10.1016/j.ajog.2008.10.049.
- Ghasi, S., Nwobodo, E. and Ofili, J. O. (2000) 'Hypocholesterolemic effects of crude extract of leaf of *Moringa oleifera* Lam in high-fat diet fed wistar rats', *Journal of Ethnopharmacology*, 69(1), pp. 21–25. doi: 10.1016/S0378-8741(99)00106-3.
- Ghimire, P. R. *et al.* (2018) 'Perinatal mortality in South Asia: Systematic review of observational studies', *International Journal of Environmental Research and Public Health*, 15(7). doi: 10.3390/ijerph15071428.
- Goedhart, G. *et al.* (2010) 'Maternal cortisol and offspring birthweight: Results from a large prospective cohort study', *Psychoneuroendocrinology*, 35(5), pp. 644–652. doi: 10.1016/j.psyneuen.2009.10.003.
- Goodman, S. H. and Tully, E. C. (2009) 'Recurrence of depression during pregnancy: Psychosocial and personal functioning correlates', *Depression and Anxiety*, 26(6), pp. 557–567. doi: 10.1002/da.20421.
- Gopalakrishnan, L., Doriya, K. and Kumar, D. S. (2016) 'Moringa oleifera: A review on nutritive importance and its medicinal application', *Food Science and Human Wellness*, 5(2), pp. 49–56. doi: 10.1016/j.fshw.2016.04.001.
- Gunaratna, N. S. *et al.* (2015) 'Multivitamin and iron supplementation to prevent periconceptional anemia in rural Tanzanian women: A randomized, controlled trial', *PLoS ONE*, 10(4), pp. 1–15. doi: 10.1371/journal.pone.0121552.
- H, A. *et al.* (2015) 'I n t e r n a t i o n a l J o u r n a l o f G y n e c o l o g y a n d O b s t e t r i c s The I n t e r n a t i o n a l F e d e r a t i o n o f G y n e c o l o g y a n d O b s t e t r i c s (F I G O) r e c o m m e n d a t i o n s o n a d o l e s c e n t , p r e c o n c e p t i o n , a n d m a t e r n a l n u t r i t i o n : “ T h i n k N u t r i t i o n F i r s t ” #', 4.
- Hadju, V., Dassir, M., *et al.* (2020) 'Effects of moringa oleifera leaves and honey supplementation during pregnancy on mothers and newborns: A review of the current evidence', *Open Access Macedonian Journal of Medical Sciences*, 8, pp. 208–214. doi: 10.3889/oamjms.2020.4670.
- Hadju, V., Marks, G. C., *et al.* (2020) 'Moringa oleifera leaf powder supplementation improved the maternal health and birth weight: A randomised controlled trial in pregnant women', *Australian Journal of*

- Herbal and Naturopathic Medicine*, 32(3), pp. 94–101. doi: 10.33235/ajhnm.32.3.94-101.
- Hafid, R. *et al.* (2022) 'The Effect of Pumpkin Seed Biscuits and Moringa Capsules on (Malondialdehyde) Levels and Birth Outcomes of Pregnant Women', 10, pp. 278–282.
- Hasni (2018) 'THE EFFECT OF THE TREATMENT WITH MORINGA LEAF FLOUR (MORINGA OLEIFERA) IN PREGNANT WOMEN ON STRESS AND CORTISOL LEVEL', *Universitas Hasanuddin : Fak. Kedokteran*.
- He, Y. *et al.* (2016) 'Folic acid supplementation, birth defects, and adverse pregnancy outcomes in Chinese women: a population-based mega-cohort study', *The Lancet*, 388, p. S91. doi: 10.1016/s0140-6736(16)32018-9.
- Hellgren, C. *et al.* (2016) 'Tandem mass spectrometry determined maternal cortisone to cortisol ratio and psychiatric morbidity during pregnancy-interaction with birth weight', *Psychoneuroendocrinology*, 69, pp. 142–149. doi: 10.1016/j.psyneuen.2016.04.006.
- Hung, T. H., Skepper, J. N. and Burton, G. J. (2001) 'In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies', *American Journal of Pathology*, 159(3), pp. 1031–1043. doi: 10.1016/S0002-9440(10)61778-6.
- Isaksson, J. *et al.* (2015) 'High maternal cortisol levels during pregnancy are associated with more psychiatric symptoms in offspring at age of nine - A prospective study from Nicaragua', *Journal of Psychiatric Research*, 71, pp. 97–102. doi: 10.1016/j.jpsychires.2015.09.016.
- Iskandar, I. *et al.* (2015) 'Effect of Moringa Oleifera Leaf Extracts Supplementation in Preventing Maternal Anemia and Low-Birth-Weight', *International Journal of Scientific and Research Publications*, 5(1), pp. 2250–3153. Available at: www.ijsrp.org.
- Jaiswal, D. *et al.* (2013) 'Role of Moringa oleifera in regulation of diabetes-induced oxidative stress', *Asian Pacific Journal of Tropical Medicine*, 6(6), pp. 426–432. doi: 10.1016/S1995-7645(13)60068-1.
- Jourabchi, Z. *et al.* (2019) 'Association Between Preconception Care and Birth Outcomes', *American Journal of Health Promotion*, 33(3), pp. 363–371. doi: 10.1177/0890117118779808.
- Karowicz-Bilinska, A., Kędziora-Kornatowska, K. and Bartosz, G. (2007) 'Indices of oxidative stress in pregnancy with fetal growth restriction',

Free Radical Research, 41(8), pp. 870–873. doi: 10.1080/10715760701291647.

Kasolo, J. N. *et al.* (2010) 'Phytochemicals and uses of *Moringa oleifera* leaves in Ugandan rural communities', *Journal of Medicinal Plants Research*, 4(9), pp. 753–757. doi: 10.5897/JMPR10.492.

Katzer, D. *et al.* (2015) 'Antioxidative status and oxidative stress in the fetal circulation at birth: the effects of time of delivery and presence of labor', *Early Human Development*, 91(2), pp. 119–124. doi: 10.1016/j.earlhumdev.2014.12.012.

Khuzaimah, A. *et al.* (2015) 'Effect of Honey and *Moringa Oleifera* Leaf Extracts Supplementation for Preventing DNA Damage in Passive Smoking Pregnancy', *International Journal of Sciences: Basic and Applied Research (IJSBAR) International Journal of Sciences: Basic and Applied Research*, 24(1), pp. 138–145. Available at: <http://gssrr.org/index.php?journal=JournalOfBasicAndApplied>.

Kim, Y. J. *et al.* (2005) 'Oxidative stress in pregnant women and birth weight reduction', *Reproductive Toxicology*, 19(4), pp. 487–492. doi: 10.1016/j.reprotox.2004.10.007.

King, J. C. (2016) 'A summary of pathways or mechanisms linking preconception maternal nutrition with birth outcomes', *Journal of Nutrition*, 146(7), pp. 1437S-1444S. doi: 10.3945/jn.115.223479.

Kovacs, C. S. (2008) 'Vitamin D in pregnancy and lactation: Maternal, fetal, and neonatal outcomes from human and animal studies', *American Journal of Clinical Nutrition*, 88(2), pp. 520–528. doi: 10.1093/ajcn/88.2.520s.

Kunwar, A. and Priyadarsini, K. . (2011) 'Free radicals, oxidative stress and importance of antioxidants in human health', *Journal of Medical and Allied Sciences*, 1(2), pp. 53–60.

Kushwaha, S., Chawla, P. and Kochhar, A. (2014) 'Effect of supplementation of drumstick (*Moringa oleifera*) and amaranth (*Amaranthus tricolor*) leaves powder on antioxidant profile and oxidative status among postmenopausal women', *Journal of Food Science and Technology*, 51(11), pp. 3464–3469. doi: 10.1007/s13197-012-0859-9.

Lassi, Z. S. *et al.* (2020) 'Effects of preconception care and periconception interventions on maternal nutritional status and birth outcomes in low-and middle-income countries: A systematic review', *Nutrients*, 12(3). doi: 10.3390/nu12030606.

- Leone, A. *et al.* (2015) 'Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of *Moringa oleifera* leaves: An overview', *International Journal of Molecular Sciences*, 16(6), pp. 12791–12835. doi: 10.3390/ijms160612791.
- Levitt, N. S. *et al.* (2000) 'Impaired glucose tolerance and elevated blood pressure in low birth rate weight, nonobese, young South African adults: Early programming of cortisol axis', *Journal of Clinical Endocrinology and Metabolism*, 85(12), pp. 4611–4618. doi: 10.1210/jc.85.12.4611.
- Li, Z. *et al.* (2017) 'Effects of Prenatal Micronutrient Supplementation on Spontaneous Preterm Birth: A Double-Blind Randomized Controlled Trial in China', *American Journal of Epidemiology*, 186(3), pp. 318–325. doi: 10.1093/aje/kwx094.
- Mandasari, M., Hadju, V. and Ariyandy, A. (2020) 'The effect of giving extracted moringa oleifera leaves plus royal jelly supplement on infant weight and length of new born of anemia pregnant woman in Takalar district', *European Journal of Molecular and Clinical Medicine*, 7(7), pp. 4952–4961. Available at: https://ejmcm.com/article_5525_7e2beb8b55e6ef9e2367118321985bd6.pdf%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=2010514433.
- Marreiro, D. do N. *et al.* (2017) 'Zinc and oxidative stress: Current mechanisms', *Antioxidants*, 6(2). doi: 10.3390/antiox6020024.
- MENON (2016) 'Placental Senescence As a Trigger for Birth', 2016, 8(2), pp. 216–229.
- Micle O, Muresan M, Antal L, Bodog F, B. A. (2012) 'The influence of homocysteine and oxidative stress on pregnancy outcome.', *J Med Life*, Feb 22;5(1).
- Min, J. *et al.* (2009) 'Effect of Oxidative Stress on Birth Sizes: Consideration of Window from Mid Pregnancy to Delivery', *Placenta*, 30(5), pp. 418–423. doi: 10.1016/j.placenta.2009.02.007.
- Mousa, A., Naqash, A. and Lim, S. (2019) 'Macronutrient and micronutrient intake during pregnancy: An overview of recent evidence', *Nutrients*, 11(2), pp. 1–20. doi: 10.3390/nu11020443.
- Muhammad Syafruddin Nurdin, Andi Imam Arundhana Thahir, V. H. (2018) 'Supplementations on Pregnant Women and the Potential of *Moringa Oleifera* Supplement to Prevent Adverse Pregnancy Outcome', *International Journal of Science and Healthcare Research*, 3(1), pp.

71–75.

- Muis, M. *et al.* (2015) 'Effect of Moringa leaves extract on occupational stress and nutritional status of pregnant women informal sector workers Masyitha', *International Journal of Current Research and Academic Review*, 3(1), pp. 252–263.
- Mulianto, N. (2020) 'Malondialdehid sebagai Penanda Stres Oksidatif pada Berbagai Penyakit Kulit', *Cermin Dunia Kedokteran*, 47(1), pp. 39–44. Available at: <http://www.cdkjournal.com/index.php/CDK/article/view/341>.
- Mustapa, Y. *et al.* (2020) 'The effect of moringa oleifera to hemoglobin levels of preconception women in the health center tibawa district tibawa, gorontalo', *Open Access Macedonian Journal of Medical Sciences*, 8(T2), pp. 104–108. doi: 10.3889/oamjms.2020.5201.
- Nadimin (2016) 'The Influence Provision of Moringa Leaf Exctracy (Moringa Oliefera) against the Level of MDA (Malondialdehyde) in Pregnant Women', *International Journal of Sciences: Basic and Applied Research (IJSBAR)*, 27(3), pp. 48–56.
- Nadimin *et al.* (2020a) 'A comparison between extract Moringa oleifera and iron tablet on prevention low birth weight in pregnant mothers in Makassar, Indonesia', *Enfermeria clinica*, 30(December), pp. 26–30. doi: 10.1016/j.enfcli.2020.02.008.
- Nadimin *et al.* (2020b) 'A comparison between extract Moringa oleifera and iron tablet on prevention low birth weight in pregnant mothers in Makassar, Indonesia', *Enfermeria Clinica*, 30(Icnph 2019), pp. 26–30. doi: 10.1016/j.enfcli.2020.02.008.
- Nath, A. *et al.* (2017) 'Effect of prenatal exposure to maternal cortisol and psychological distress on infant development in Bengaluru, southern India: A prospective cohort study', *BMC Psychiatry*, 17(1), pp. 1–6. doi: 10.1186/s12888-017-1424-x.
- Negi, R. *et al.* (2012) 'Evaluation of biomarkers of oxidative stress and antioxidant capacity in the cord blood of preterm low birth weight neonates', *Journal of Maternal-Fetal and Neonatal Medicine*, 25(8), pp. 1338–1341. doi: 10.3109/14767058.2011.633672.
- Nguyen, P. H. *et al.* (2016) 'Impact of preconception micronutrient supplementation on anemia and iron status during pregnancy and postpartum: A randomized controlled trial in Rural Vietnam', *PLoS ONE*, 11(12), pp. 1–16. doi: 10.1371/journal.pone.0167416.

- Nguyen, P. H. *et al.* (2017) 'Preconception micronutrient supplementation with iron and folic acid compared with folic acid alone affects linear growth and fine motor development at 2 years of age: A randomized controlled trial in Vietnam', *Journal of Nutrition*, 147(8), pp. 1593–1601. doi: 10.3945/jn.117.250597.
- Nishigori, H. *et al.* (2019) 'Preconception folic acid supplementation use and the occurrence of neural tube defects in Japan: A nationwide birth cohort study of the Japan Environment and Children's Study', *Congenital Anomalies*, 59(4), pp. 110–117. doi: 10.1111/cga.12293.
- No Atiba AS, Abbiyesuku FM, Adekanle DA, Oparinde DP, Ajose OA, N.-A. T. (2014) 'Malondialdehyde and antioxidant enzymes in second and third trimesters of pre-eclamptic Nigerian women', *Niger Postgrad Med J.*, Jun;21(2):
- Nur, R. *et al.* (2020) 'The effect of moringa leaf extracton increasing hemoglobin and bodyweight in post-disaster pregnant women', *Enfermeria Clinica*, 30(1cnp 2019), pp. 79–82. doi: 10.1016/j.enfcli.2019.10.045.
- Ota, E. *et al.* (2011) 'Indice maternel de masse corporelle et augmentation du poids en gestation et leur association avec les observations périnatales au Viet Nam', *Bulletin of the World Health Organization*, 89(2), pp. 127–136. doi: 10.2471/BLT.10.077982.
- Otoluwa, A. *et al.* (2014) 'Effect of Moringa Oleifera Leaf Extracts Supplementation in Preventing Maternal DNA Damage', *International Journal of Scientific and Research Publications*, 4(11), pp. 2250–3153. Available at: www.ijsrp.org.
- P, W. F. *et al.* (2020) 'The Effect of Moringa Oleifera Leaves Plus Royal Jelly Supplement on Cortisol Hormone and Stress Levels on Anemia of Pregnant Women in Takalar Regency', *Journal La Lifesci*, 1(3), pp. 30–36. doi: 10.37899/journallalifesci.v1i3.189.
- Paikra, B. K., Dhongade, H. K. J. and Gidwani, B. (2017) 'Phytochemistry and pharmacology of Moringa oleifera Lam', *Journal of Pharmacopuncture*, 20(3), pp. 194–200. doi: 10.3831/KPI.2017.20.022.
- Pais, M. and Pai, M. V. (2018) 'Stress among pregnant women: A systematic review', *Journal of Clinical and Diagnostic Research*, 12(5), pp. LE01–LE04. doi: 10.7860/JCDR/2018/30774.11561.
- Panda, S. *et al.* (2013) 'Cardioprotective potential of N, α -l-rhamnopyranosyl vincosamide, an indole alkaloid, isolated from the leaves of Moringa

oleifera in isoproterenol induced cardiotoxic rats: In vivo and in vitro studies', *Bioorganic and Medicinal Chemistry Letters*, 23(4), pp. 959–962. doi: 10.1016/j.bmcl.2012.12.060.

- Pathak, R. *et al.* (2010) 'Organochlorine pesticide residue levels and oxidative stress in preterm delivery cases', *Human and Experimental Toxicology*, 29(5), pp. 351–358. doi: 10.1177/0748233710363334.
- Pérez-Rodríguez, R. *et al.* (2017) 'Un modelo de probabilidad implementado en la solución de ruteo de autobuses escolares con selección de paradas', *Dyna (Spain)*, 92(2), p. 138. doi: 10.6036/8204.
- Phillips, D. I. W. *et al.* (2000) 'Low birth weight predicts elevated plasma cortisol concentrations in adults from 3 populations', *Hypertension*, 35(6), pp. 1301–1306. doi: 10.1161/01.HYP.35.6.1301.
- Phithakwatchara, N. and Titapant, V. (2007) 'The effect of pre-pregnancy weight on delivery outcome and birth weight in potential diabetic patients with normal screening for gestational diabetes mellitus in Siriraj Hospital', *Journal of the Medical Association of Thailand*, 90(2), pp. 229–236.
- Pisoschi, A. M. and Pop, A. (2015) 'The role of antioxidants in the chemistry of oxidative stress: A review', *European Journal of Medicinal Chemistry*, 97, pp. 55–74. doi: 10.1016/j.ejmech.2015.04.040.
- Potdar, R. D. *et al.* (2014) 'Improving women's diet quality preconceptionally and during gestation: Effects on birth weight and prevalence of low birth weight - A randomized controlled efficacy trial in India (Mumbai maternal nutrition project)', *American Journal of Clinical Nutrition*, 100(5), pp. 1257–1268. doi: 10.3945/ajcn.114.084921.
- Rabiepour, S., Saboory, E. and Abedi, M. (2019) 'The relationship between stress during pregnancy with leptin and cortisol blood concentrations and complications of pregnancy in the mother', *Journal of the Turkish German Gynecology Association*, 20(4), pp. 218–223. doi: 10.4274/jtgga.galenos.2019.2019.0010.
- Rajendran, S. *et al.* (2022) 'Differences in the response to iron supplementation on oxidative stress, inflammation, and hematological parameters in nonanemic and anemic pregnant women', *Journal of Maternal-Fetal and Neonatal Medicine*, 35(3), pp. 465–471. doi: 10.1080/14767058.2020.1722996.
- Rallis, S. *et al.* (2014) 'A prospective examination of depression, anxiety and stress throughout pregnancy', *Women and Birth*, 27(4), pp. e36–e42.

doi: 10.1016/j.wombi.2014.08.002.

- Ramakrishnan, U. *et al.* (2012) 'Effect of women's nutrition before and during early pregnancy on maternal and infant outcomes: A systematic review', *Paediatric and Perinatal Epidemiology*, 26(SUPPL. 1), pp. 285–301. doi: 10.1111/j.1365-3016.2012.01281.x.
- Rayco-Solon, P., Fulford, A. J. and Prentice, A. M. (2005) 'Maternal preconceptional weight and gestational length', *American Journal of Obstetrics and Gynecology*, 192(4), pp. 1133–1136. doi: 10.1016/j.ajog.2004.10.636.
- Razis, A. F. A., Ibrahim, M. D. and Kntayya, S. B. (2014) 'Health benefits of Moringa oleifera', *Asian Pacific Journal of Cancer Prevention*, 15(20), pp. 8571–8576. doi: 10.7314/APJCP.2014.15.20.8571.
- De Regil, L. M. *et al.* (2009) 'Effects and safety of periconceptional folate supplementation for preventing birth defects', *Cochrane Database of Systematic Reviews*, (3). doi: 10.1002/14651858.CD007950.
- Reski, R. N. *et al.* (2020) 'Anemia, chronic energy deficiency and their relationship in preconception women', *Enfermeria Clínica*, 30, pp. 76–80.
- Ronnenberg, A. G. *et al.* (2003) 'Low Preconception Body Mass Index Is Associated with Birth Outcome in a Prospective Cohort of Chinese Women', *Journal of Nutrition*, 133(11), pp. 3449–3455. doi: 10.1093/jn/133.11.3449.
- Ronnenberg, A. G. *et al.* (2004) 'Preconception hemoglobin and ferritin concentrations are associated with pregnancy outcome in a prospective cohort of Chinese women', *Journal of Nutrition*, 134(10), pp. 2586–2591. doi: 10.1093/jn/134.10.2586.
- Saa, R. W. *et al.* (2019) 'Treatments and uses of Moringa oleifera seeds in human nutrition: A review', *Food Science and Nutrition*, 7(6), pp. 1911–1919. doi: 10.1002/fsn3.1057.
- Schoots, M. H. *et al.* (2018) *Oxidative stress in placental pathology, Placenta*. Elsevier Ltd. doi: 10.1016/j.placenta.2018.03.003.
- Scifres, C. M. and Nelson, D. M. (2009) 'Intrauterine growth restriction, human placental development and trophoblast cell death', *Journal of Physiology*, 587(14), pp. 3453–3458. doi: 10.1113/jphysiol.2009.173252.

- Shapiro, G. D. *et al.* (2013) 'Psychosocial stress in pregnancy and preterm birth: Associations and mechanisms', *Journal of Perinatal Medicine*, 41(6), pp. 631–645. doi: 10.1515/jpm-2012-0295.
- Singh, B. N. *et al.* (2009) 'Oxidative DNA damage protective activity, antioxidant and anti-quorum sensing potentials of *Moringa oleifera*', *Food and Chemical Toxicology*, 47(6), pp. 1109–1116. doi: 10.1016/j.fct.2009.01.034.
- Situmorang, N. and Zulham, Z. (2020) 'Malondialdehyde (Mda) (Zat Oksidan Yang Mempercepat Proses Penuaan)', *Jurnal Keperawatan Dan Fisioterapi (Jkf)*, 2(2), pp. 117–123. doi: 10.35451/jkf.v2i2.338.
- Skouteris, H. *et al.* (2009) 'Depression and anxiety through pregnancy and the early postpartum: An examination of prospective relationships', *Journal of Affective Disorders*, 113(3), pp. 303–308. doi: 10.1016/j.jad.2008.06.002.
- Spencer, T. E. *et al.* (2004) 'Implantation mechanisms: Insights from the sheep', *Reproduction*, 128(6), pp. 657–668. doi: 10.1530/rep.1.00398.
- Stacey, T. *et al.* (2011) 'The Auckland stillbirth study, a case-control study exploring modifiable risk factors for third trimester stillbirth: Methods and rationale', *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 51(1), pp. 3–8. doi: 10.1111/j.1479-828X.2010.01254.x.
- Stein, T. P. *et al.* (2008) 'Oxidative stress early in pregnancy and pregnancy outcome', *Free Radical Research*, 42(10), pp. 841–848. doi: 10.1080/10715760802510069.
- Stewart, C. P. *et al.* (2015) 'Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: An analysis of data from a randomized controlled trial in rural Malawi', *BMC Pregnancy and Childbirth*, 15(1), pp. 1–12. doi: 10.1186/s12884-015-0793-8.
- Suhartatik *et al.* (2020) 'Affect of moringa oleifera given against pregnant and breastfeeding mothers cortisol', *Enfermeria Clinica*, 30, pp. 91–94. doi: 10.1016/j.enfcli.2019.10.048.
- Sultana, Z. *et al.* (2017) 'Oxidative stress, placental ageing-related pathologies and adverse pregnancy outcomes', *American Journal of Reproductive Immunology*, 77(5), pp. 1–10. doi: 10.1111/aji.12653.

- Suzana, D. *et al.* (2017) 'Effect of moringa oleifera leaves extract against hematology and blood biochemical value of patients with iron deficiency anemia', *Journal of Young Pharmacists*, 9(1), pp. S79–S84. doi: 10.5530/jyp.2017.1s.20.
- Thomas, M. and Weisman, S. M. (2006) 'Calcium supplementation during pregnancy and lactation: Effects on the mother and the fetus', *American Journal of Obstetrics and Gynecology*, 194(4), pp. 937–945. doi: 10.1016/j.ajog.2005.05.032.
- Thongsomboon, W., Kaewkiattikun, K. and Kerdcharoen, N. (2020) 'Perceived stress and associated factors among pregnant women attending antenatal care in urban thailand', *Psychology Research and Behavior Management*, 13, pp. 1115–1122. doi: 10.2147/PRBM.S290196.
- Timmermans, S. *et al.* (2009) 'Periconception folic acid supplementation, fetal growth and the risks of low birth weight and preterm birth: The Generation R Study', *British Journal of Nutrition*, 102(5), pp. 777–785. doi: 10.1017/S0007114509288994.
- Traylor, C. S. *et al.* (2020) 'Effects of psychological stress on adverse pregnancy outcomes and nonpharmacologic approaches for reduction: an expert review', *American journal of obstetrics & gynecology MFM*, 2(4), p. 100229. doi: 10.1016/j.ajogmf.2020.100229.
- Ulmy, M. N. *et al.* (2020) 'Effect of moringa leaves during pregnancy on growth and morbidity in 0–5 months', *Enfermeria Clinica*, 30, pp. 61–65. doi: 10.1016/j.enfcli.2019.10.041.
- Wang, H. *et al.* (2016) 'Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015', *The Lancet*, 388(10053), pp. 1725–1774. doi: 10.1016/S0140-6736(16)31575-6.
- Wang, Y. *et al.* (2015) 'Folic acid supplementation, preconception body mass index, and preterm delivery: Findings from the preconception cohort data in a Chinese rural population', *BMC Pregnancy and Childbirth*, 15(1), pp. 1–9. doi: 10.1186/s12884-015-0766-y.
- Weber, D. *et al.* (2014) 'Oxidative stress markers and micronutrients in maternal and cord blood in relation to neonatal outcome', *European Journal of Clinical Nutrition*, 68(2), pp. 215–222. doi: 10.1038/ejcn.2013.263.

- Wisitpongpun, P. *et al.* (2020) 'In vitro bioassay-guided identification of anticancer properties from moringa oleifera lam. Leaf against the mda-mb-231 cell line', *Pharmaceuticals*, 13(12), pp. 1–20. doi: 10.3390/ph13120464.
- Yekti, R. *et al.* (2018) 'International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) Peroxidation', 6(4), pp. 6–8.
- Zakaria *et al.* (2016) 'Effect of Extract Moringa Oleifera on Quantity and Quality of Breastmilk In Lactating Mothers, Infants 0-6 Month', *Jurnal MKMI*, 12(3), pp. 161–169.
- Zakiah, V., Hadju, V. and Ariyandy, A. (2020) 'The Effect Of Giving The Supplement Of Kelor Leaves (Moringa Oleifera Leaves) Plus Royal Jelly To Malondialdehyd Levels In Anemic Pregnant Women In Takalar District', 07(06), pp. 711–716.
- Zeng, B. *et al.* (2019) 'The beneficial effects of Moringa oleifera leaf on reproductive performance in mice', *Food Science and Nutrition*, 7(2), pp. 738–746. doi: 10.1002/fsn3.918.

LAMPIRAN

LAMPIRAN 1

INFORM CONSENT

Pengaruh Kadar Mda (*Malondialdehyde*) Dan Kortisol Dengan Luaran Kehamilan Pada Ibu Hamil Yang Mendapat Intervensi Ekstrak Daun Kelor (*Moringa Oleifera*) Sejak Masa Prakonsepsi Di Kabupaten Takalar

Assalamualaikum wr. wb

Yang terhormat Ibu, perkenalkan nama kami dr. Rahma dan tim, pada kesempatan kali ini kami mohon kesediaan Ibu untuk berkenan menjadi responden penelitian dengan judul tersebut di atas, sehingga kami akan menanyakan kepada Ibu beberapa pertanyaan yang berkaitan dengan Sanitasi dan Kesehatan, serta kesediaan pengambilan sampel darah. Untuk jawaban yang Ibu berikan dan hasil pemeriksaan darah tersebut akan kami kaji dan senoga kedepan akan menjadi informasi dan bermanfaat bagi peningkat program kesehatan di kabupaten Takalar dan kami menjamin kerahasiaannya.

Apakah Ibu bersedia menjadi responden pada penelitian ini?

1. Ya
2. Tidak

Atas bantuan dan kesediaan waktu yang telah Ibu berikan, kami ucapkan terimakasih. Wassalamualaikum wr. wb.

LEMBAR PERSETUJUAN (INFORM COSENT)

Setelah mendengar penjelasan tentang mengenai tujuan penelitian, prosedur penelitian, manfaat dan inti dari kuesioner ini. Saya mengerti bahwa:

- Pada diri saya akan dilakukan wawancara sesuai dengan pertanyaan pada kuesioner Maka dengan ini saya yang bertanda tangan di bawah ini:

Nama ibu : _____
 Umur : _____ tahun
 Alamat : _____
 Wilayah Puskesmas : _____
 Usia Kehamilan : _____
 No. Telepon : _____

Menyatakan setuju untuk berpartisipasi sebagai subyek penelitian ini secara sukarela dan bebas tanpa ada paksaan, dengan catatan apabila merasa dirugikan dalam penelitian ini dalam bentuk apapun berhak membatalkan persetujuan ini.

_____, tanggal __/__/2021

Pembuat pernyataan,

(_____)

LAMPIRAN 2

Kuesioner Depression Anxiety Stress Scale (DASS 42)

Petunjuk Pengisian Kuesioner ini terdiri dari berbagai pernyataan yang mungkin sesuai dengan pengalaman Ibu dalam menghadapi situasi hidup sehari-hari selama hamil. Terdapat empat pilihan jawaban yang disediakan untuk setiap pernyataan yaitu: tidak pernah, kadang-kadang, lumayan sering dan Sering sekali.

Selanjutnya, Ibu diminta untuk menjawab dengan cara memberi tanda centang (√) pada salah satu kolom yang paling sesuai dengan pengalaman Ibu saat ini. Tidak ada jawaban yang benar ataupun salah, karena itu isilah sesuai dengan keadaan diri Ibu yang sesungguhnya, yaitu berdasarkan jawaban pertama yang terlintas dalam pikiran Ibu.

1. Saya merasa bahwa diri saya menjadi marah karena hal-hal sepele.

- Tidak Pernah
- Kadang-kadang
- Lumayan Sering
- Sering Sekali

2. Saya cenderung bereaksi berlebihan terhadap suatu situasi.

- Tidak Pernah
- Kadang-kadang
- Lumayan Sering
- Sering Sekali

3. Saya merasa sulit untuk bersantai.

- Tidak Pernah
- Kadang-kadang
- Lumayan Sering
- Sering Sekali

4. Saya menemukan diri saya mudah merasa kesal.

- Tidak Pernah
- Kadang-kadang
- Lumayan Sering

- Sering Sekali
5. Saya merasa telah menghabiskan banyak energi untuk merasa cemas.
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering
 Sering Sekali
6. Saya menemukan diri saya menjadi tidak sabar ketika mengalami penundaan (misalnya: kemacetan lalu lintas, menunggu sesuatu).
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering
 Sering Sekali
7. Saya merasa bahwa saya mudah tersinggung.
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering
 Sering Sekali
8. Saya merasa sulit untuk beristirahat.
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering
 Sering Sekali
9. Saya merasa bahwa saya sangat mudah marah.
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering
 Sering Sekali
10. Saya merasa sulit untuk tenang setelah sesuatu membuat saya kesal.
- Tidak Pernah
 Kadang-kadang
 Lumayan Sering

Sering Sekali

11. Saya sulit untuk sabar dalam menghadapi gangguan terhadap hal yang sedang saya lakukan.

Tidak Pernah

Kadang-kadang

Lumayan Sering

Sering Sekali

12. Saya sedang merasa gelisah.

Tidak Pernah

Kadang-kadang

Lumayan Sering

Sering Sekali

13. Saya tidak dapat memaklumi hal apapun yang menghalangi saya untuk menyelesaikan hal yang sedang saya lakukan

Tidak Pernah

Kadang-kadang

Lumayan Sering

Sering Sekali

14. Saya menemukan diri saya mudah gelisah.

Tidak Pernah

Kadang-kadang

Lumayan Sering

Sering Sekali

LAMPIRAN 3

SOP PENGAMBILAN DARAH VENA DAN SALIVA PENELITIAN EKSTRAK DAUN KELOR DAN IFA DI KECAMATAN POLOMBANGKENG KABUPATEN TAKALAR

1. Pengambilan darah vena sebaiknya dilakukan pada pagi hari sebelum sarapan setelah tidak makan selama 8-10 jam, apabila tidak memungkinkan dilakukan pada waktu kapanpun sepanjang hari.
2. Pengambilan saliva dapat dilakukan pada pukul 06.00-12.00.
3. Pengambilan darah vena dilakukan oleh petugas kesehatan terampil seperti perawat atau analis
4. Darah vena ditampung di tabung vacutainer EDTA warna ungu untuk pemeriksaan hematologi dan vacutainer merah untuk pemeriksaan kimia klinik dan imunologi.
5. Pengambilan saliva dilakukan oleh subjek penelitian sendiri dan ditampung dalam tabung merah
6. Tabung darah dan saliva diberi label dan dicantumkan nama, umur dan kode sampel yang disepakati peneliti.
7. Sampel didata dan diberi kode untuk memudahkan penyusunan dan penelusuran data
8. Pemberian kode dilakukan oleh enumerator
9. Darah EDTA sebaiknya langsung diperiksa dengan alat pemeriksaan Hematology analyzer 5 diff dan apabila tdk memungkinkan disimpan di lemari es suhu 2-8 °C hingga 2 hari
10. Pemisahan serum dilakukan dari tabung merah dengan sentrifus 10 menit 3500 rpm. Serum dipisahkan dalam cup-cup sampel minimal 1 ml per cup sampel, diusahakan sebanyak mungkin cup sampel (replikasi) untuk mengantisipasi pengulangan pemeriksaan.
11. Serum dan saliva dapat disimpan di freezer suhu -20°C atau -80°C hingga pemeriksaan dilakukan
12. Pengiriman serum/darah EDTA/saliva ke Makassar dilakukan dengan tromol es untuk menjaga suhu sampel darat.
13. Sampel yang di terima di Laboratorium humRC UNHAS dan disimpan dalam lemari es hingga waktu pemeriksaan sampel.
14. Sampel serum dan saliva diperiksa dengan metode ELISA
15. Hasil pemeriksaan dikirimkan ke peneliti dalam bentuk excel.
16. Sisa sampel serum disimpan hingga 6 bulan sejak pengambilan sampel apabila dibutuhkan di kemudian hari

LAMPIRAN 4 Rekomendasi Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KESEHATAN MASYARAKAT
Jln.Perintis Kemerdekaan Km.10 Makassar 90245, Telp.(0411) 585658,
E-mail : fkunhas@gmail.com, website: <https://fkunhas.ac.id/>

REKOMENDASI PERSETUJUAN ETIK

Nomor : 4885/UN4.14.1/TP.02.02/2021

Tanggal : 2 Agustus 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No.Protokol	05111993029	No. Sponsor Protokol	
Peneliti Utama	Rahma	Sponsor	Pribadi
Judul Peneliti	Hubungan antara Kadar MDA (Malondyaldehide) dan Kortisol dengan Luaran Kehamilan Pada Ibu Hamil Yang Mendapat Intervensi Ekstrak Daun Kelor Sejak Masa Prakonsepsi Di Kabupaten Takalar		
No.Versi Protokol	1	Tanggal Versi	5 November 2019
No.Versi PSP	1	Tanggal Versi	5 November 2019
Tempat Penelitian	Kecamatan Polongbangkeng Utara Kabupaten Takalar		
Judul Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard	Masa Berlaku 2 Agustus 2022 Sampai 2 Agustus 2023	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian	Nama : Prof.dr.Veni Hadju,M.Sc,Ph.D	Tanda tangan 	Tanggal  2 Agustus 2022
Sekretaris komisi Etik Penelitian	Nama : Dr. Wahiduddin, SKM.,M.Kes	Tanda tangan 	Tanggal 2 Agustus 2022

Kewajiban Peneliti Utama :

1. Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
2. Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
3. Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
4. Menyerahkan laporan akhir setelah Penelitian berakhir
5. Melaporakan penyimpangan dari protocol yang disetujui (protocol deviation/violation)
6. Mematuhi semua peraturan yang ditentukan

LAMPIRAN 5. Food Recall

NO	NAMA	Energi	Karbo	Protein	Lemak	Serat	Vit.C	Vit.A	Chols	Vit.B1	Vit.B2	Vit.B6	Vit.E	FE	Asam.Folat	Natrium	Kalium	Kalsium	Magnesium	Fosfor	Zinc
1	Risna	1451	224.9	68.7	30	11	47.3	548.5	372.6	0.5	0.7	1.4	7.9	5.4	183.5	232.5	1516.7	186.5	194	761.1	4.4
2	Hartina B	2064.8	299.7	83.8	73	60.6	83.4	1251.9	355.6	1.2	1.8	2.9	10.7	64.6	607.7	681.1	4903	2031.3	621.1	1959.4	15.2
3	Harianti	1645.6	276.8	43.2	38.8	10.8	24.6	227.6	85	0.6	0.3	1	6	4.2	108.5	84.9	1449.7	98.3	176.8	726	4.4
4	Karmila	2023.9	227	84.4	82.6	3.3	4.8	356.4	497.8	0.6	1.4	1.2	2.8	5.3	95.8	727.3	1618.1	536.2	196.1	1193.9	11.1
5	Vani	1041.2	185.2	38.4	13.6	3.2	36.1	27.5	91.8	0.5	0.3	0.5	4.2	1.8	28.8	65.3	832.6	40.5	120.9	618.4	3.2
6	Nurhalipah	1623	259.1	36	56.6	19.1	60.4	959.5	29.5	0.6	0.6	2.6	5.4	7.3	235.9	84	2688.8	215.5	281.8	515.6	5
7	Berliana Farensia	1897.6	329	52	36.4	10.9	4.3	25.8	87	0.3	0.3	0.4	1.5	14.3	103.9	1779.1	7160.6	654.5	827	915.8	5.1
8	Nurlela	888.6	152.9	49.3	6.8	4.3	7.2	52.4	95.5	0.3	0.3	1.1	1.5	2.8	46.2	93.8	1164.8	65.8	176.2	623	4.1
9	Arfiani Arfa	2520.9	363.5	146.5	50.6	20.6	110	1359	107	1.3	2	2.2	8	30.9	576.3	3679.8	4705.3	3551.3	552.5	3209.5	18.3
10	St. Magfirah Nasir	1289.9	115.4	82.4	51.7	2.7	1.3	142.2	436.2	0.4	0.7	0.9	2.3	5.3	52.8	242.2	1056.1	64.9	121.6	836	9.3
11	Asriani	2159.1	326.7	82	58.4	12.5	231.3	1376.8	87.5	1.3	1.6	1.3	13	20.7	399.8	1125.5	3435.8	1707.8	329.8	1792.3	11.4
12	Selviana	1646.7	240.4	76.2	40.2	9.4	72.8	945.8	368.9	0.8	1.3	1.2	9.6	13.6	212.9	492.9	2561.9	985.3	287.5	1387.1	8.1
13	Muliana	1400.8	244	61.1	17.4	10.8	6.3	311	202.5	0.8	0.4	0.7	4.7	5.3	262	120	1402	91.6	198.5	1015.1	5.4
14	Darmawati	1556.4	225.5	76	35.9	7.6	23.8	545.8	184.5	0.8	0.6	0.9	4.5	4.6	110.8	610.5	1484.6	107.4	201.1	1026.4	6
15	Hasnawati	1327.6	210.2	35.2	40.4	12.9	30.2	519.4	71.8	0.4	0.4	0.7	3.2	5.1	113.2	99.8	856.2	119.8	140.2	408.2	3.9
16	Asdiana	1402.7	225.4	53.6	28.6	5.2	66	195.1	97	0.3	0.3	0.9	2.6	3.9	74.8	98.4	1175.2	100.9	202.2	614.8	5.5
17	Nurwana	1346.8	256.1	53.9	12.5	15.8	63.2	733.8	64	0.4	0.4	1.3	4.1	5.2	140.6	1469.7	1322.1	157.5	200.1	554.4	4.1
18	Nirwana	1365.8	223.1	50	29.9	9.7	29.4	560.3	88.8	0.4	0.6	1.1	0.4	5.3	75	2140.3	1242.3	86	165.6	532.6	5.3
19	Ichrani	903.3	157.9	31.6	16.3	8.3	18.3	171.6	69.6	0.4	0.2	0.5	4	3.4	109	2005	1022.5	99.2	122.7	541.3	2.9
20	Nurbia	1286.1	249	38.3	11.3	8.4	102.2	1133.1	75.4	0.6	0.4	0.9	6.7	3.3	137.6	523	4257.6	441.2	456.6	786.5	3.6
21	Nurwahida Tais	1127.3	196.2	44.6	17.4	7.1	62.8	816	87	0.6	0.6	1.1	4.1	7	214.4	85.2	1684.7	341.8	212.7	738.3	4.1
22	Rahmatia	1002.7	177.7	32.8	17.4	7.5	22.9	195.2	266.9	0.4	0.7	1.1	2.5	3.7	104.6	657	1262.6	118.8	161.9	542	3.9
23	Jumriani	2256.9	293.3	131.1	58	8.4	33.7	508	173.3	0.6	1.2	1.7	2.2	9.1	162.8	904.5	2454.1	2346.3	378.4	2290.5	12.8
24	Nur Mitsna	2054.9	171	46.8	139.5	15.6	30.4	931.5	508.8	0.6	1.1	1.7	10.5	7.8	222.2	184.8	1917	217.3	282.9	703.2	6.1

NO	NAMA	Energi	Karbo	Protein	Lemak	Serat	Vit.C	Vit.A	Chols	Vit.B1	Vit.B2	Vit.B6	Vit.E	FE	Asam.Folat	Natrium	Kalium	Kalsium	Magnesium	Fosfor	Zinc
25	Sumira	1758.6	164.9	50.8	104	10.3	58.3	474	92.4	0.4	0.4	0.9	3.8	13.9	69.8	112.6	1106.1	264.4	304	516.4	5.2
26	Fatimah	2400.1	406.6	91.3	41.3	6.7	11.8	213	265.5	0.5	0.8	1.1	3.6	9.2	106.1	349.4	1644.9	1621.4	286.6	1683.3	9.2
27	Nurhana	1803.8	300.7	54.8	39.6	6.9	103.9	440	490.5	0.4	1	1	4.4	4.5	140.2	188.9	1189.4	136.3	168.7	686.8	6
28	Hamriani	1569.9	209.2	59.9	53	5.7	8.6	224.5	134.1	0.3	0.6	0.7	1.1	4.7	64.1	1002.9	705.2	189.1	134.4	626.4	6
29	Kasmiasi	1809.8	246.8	46	71.7	8	70.2	640.3	259.6	0.6	0.6	0.8	6.8	4.6	96.6	115.6	1167.2	116	135.3	609.9	4
30	Chaerunnisa	2484.3	260.3	107.5	109.2	2	8.4	434.1	472	0.7	2.2	1.5	0	6.1	96.9	653.5	2114.9	1054.7	234.3	1556.8	13.4
31	Hasnawati balangtanaya	544.7	89.7	18.5	13.4	5	45.7	122.9	47	0.4	0.3	0.4	0	3	55.5	77.1	717.8	189.2	81.6	411.7	2.1
32	Hasnawati panrannuangku	2242.3	401.8	74.8	32.5	7.3	12.9	105.4	138.4	0.6	0.6	1.4	0	4.3	86.2	556.9	3875.4	406.4	481.3	965.6	5.6
33	Jumriani	476.9	102.6	12.3	1.5	4.3	34.8	10.6	14.5	0.3	0.1	0.5	0	2.2	86.4	13.7	507.4	37.5	59.9	265.3	1.7
34	Narti	2230	371.4	85.7	44.7	9.5	43.2	558.8	180.5	0.9	2.7	2	0	5.2	181.6	1219.1	3267.6	1729.4	340.9	1840.8	10.1
35	Nur Ida	2186.5	456.3	62.9	6.4	8.2	19.2	117.8	401.2	0.6	0.5	1.5	0	4.4	84.7	81.9	1300.6	89	266.5	878.2	6.9
36	Nur Wahidah	1973.7	297.8	78	52.2	5.5	83.3	711.3	65.5	0.8	1.3	1.1	0	16.1	161.7	591.1	2149.4	1096.2	290.7	1411.5	10.2
37	Nuraeni	1048	203.7	38.8	9.3	8.1	27.2	234.7	80.8	0.7	0.3	0.5	0	3.3	149.7	318.9	1083.6	81.6	160.3	685	3.8
38	Nurfaika	3388.9	525.4	133.1	82.4	9.4	77.3	990.7	322.4	1.8	3	2.6	0	10	273.1	903.1	4850.9	1932.2	512.6	2758.4	13.8
39	Sri Nurhildah	3583.4	528	110.6	110.9	6	21.5	259.2	97.2	0.7	0.9	1.7	0	11.5	108.9	350.7	3086.3	262	343.3	1306.1	14.7
40	Putri Rahayu	1665.8	289.7	51.8	28.7	5.3	3.4	88.2	369	0.3	0.4	0.8	0	5.6	49.3	1895.8	1811.4	211.9	317.2	623.4	5.3
41	Selfiyanti	815.3	142	18.9	19.1	4.8	8.8	21.3	61.5	0.2	0.1	0.3	0	4	42.5	6.6	377.3	73.1	131.3	279.1	2.7
42	Sitti Suhartinah	2106.8	369.7	67.4	37.1	10.7	39.9	520.3	0	0.8	0.6	1.1	0	7.5	210.5	118.4	1623	177.7	321.5	1062.6	7.4
43	Vina	906.3	196.4	13.5	6.5	6	38.7	429.9	6.5	0.3	0.2	0.6	0	2.3	61.7	209.7	2175.2	215.7	198.6	322.6	2.3
44	Yusniar	924.6	194.8	23	3.3	3.6	13	28.8	23.2	0.3	0.2	0.4	0	2.1	40.4	22.3	491.9	50.7	107.2	363	3
45	Yusriani	805.7	147.1	30.4	8.7	2.5	2.6	50.1	14.3	0.2	0.2	0.4	0	2.5	49.5	83.4	510.9	463.2	124.9	563.9	3.7
46	Samsinar	1031	150.6	42.5	26.8	6	25.6	561.2	745.7	0.3	1.1	0.7	6.5	4.3	145	246.5	810.5	176.5	118.1	607.2	4
47	Ramlah Aulia	1102	141.8	34.8	45.7	6.3	9	137.2	11.3	0.3	0.3	0.5	0.4	10.7	88.4	318.4	687	250.6	257.3	455.4	3.6
48	Nurfitra Wulandari	1091	161.6	35	34	3.5	17	9.8	25	0.4	0.2	0.7	3	3.6	67.8	23.5	740.8	112	137	496.5	3.8
49	Asti	1397.9	249.1	43.4	23.9	5.5	11.8	224.1	97.1	0.5	0.6	0.6	5.6	3.2	83.3	168.8	1070.7	286.7	133.9	763.7	4.1
50	Julianti	2002.3	346.9	64.2	37.2	8.8	10.2	1199.2	847.7	0.5	1.7	0.8	5	6.2	186.8	862.9	1210.6	557.2	203.7	1031.8	7.2

NO	NAMA	Energi	Karbo	Protein	Lemak	Serat	Vit.C	Vit.A	Chols	Vit.B1	Vit.B2	Vit.B6	Vit.E	FE	Asam.Folat	Natrium	Kalium	Kalsium	Magnesium	Fosfor	Zinc
51	Mirtawati	1778	254.1	57.2	57.2	16.9	5.1	112.6	90.7	0.4	0.7	1	2	4.8	61.7	139.6	924.8	225.8	183.3	680	6.3
52	Rosminawati	2551.1	476.5	72.7	39.7	3.5	50.3	342.9	138.4	0.8	1.5	1.2	2	5.5	158.2	1276.3	2261.2	944.8	288.1	1439.7	7.8
53	Sri Ismayanti	961.9	205	23.1	4.2	1	18.5	16.3	29	0.3	0.3	1	1.3	1.9	41.3	21.5	822.8	33.8	126.3	368.8	2.9
54	Supiati	813.9	140.8	28.7	13.4	4.4	54	142	302.4	0.3	0.5	0.5	2.2	2.1	78.9	114.4	588.8	94.3	92	346.5	2.8
55	Sumarni	1160.4	146.7	51	40.3	14.8	2.8	34.5	87.1	0.3	0.3	0.8	3.3	3.5	68.1	95.1	734	108.4	164	498.8	4.2
56	Israwati	761.6	148.9	27.4	3.4	1	0.8	10.8	54.8	0.3	0.2	0.4	1.6	1.5	18.8	38.3	453.5	24.3	88.6	410.9	2.9
57	Mayanti	2016.3	364.9	70.6	31.5	9.8	210.8	345.5	114.6	1	1.1	2.2	7.5	5.1	121.3	299.7	2703.9	957.6	306.4	1314.2	8
58	Mirawati	879.3	145.5	39	16.7	3	129	64.5	106.3	0.3	0.5	0.8	3	3	36.3	82.5	850.8	57	93.8	368.8	4.4
59	Ramlah	931.8	108.7	44.9	32.8	8.6	16	353.7	745.6	0.4	1	0.5	5.6	3.3	102.2	251.2	763.4	129.6	94.3	675.9	3.9

LAMPIRAN 6

T-Test

Notes

Output Created		10-OCT-2022 13:23:47
Comments		
Input	Data Active Dataset Filter Weight Split File N of Rows in Working Data File Definition of Missing	D:\Dr. RAHMA\Untitled1.sav DataSet1 <none> <none> <none> 56 User defined missing values are treated as missing.
Missing Value Handling	Cases Used	Statistics for each analysis are based on the cases with no missing or out-of-range data for any variable in the analysis. T-TEST GROUPS=KodeKapsul('1' '2') /MISSING=ANALYSIS /VARIABLES=MDA Kortisol BBL PBL DASS42 /CRITERIA=CI(.95).
Syntax		
Resources	Processor Time Elapsed Time	00:00:00,02 00:00:00,02

[DataSet1] D:\Dr. RAHMA\Untitled1.sav

Group Statistics

	Kode Kapsul	N	Mean	Std. Deviation	Std. Error Mean
MDA	IFA	30	49.25500611	.784173894	.143169910
	Kelor+IFA	26	47.58289255	8.355324773	1.638614002
Kortisol	IFA	30	70.56087746	30.008673657	5.478809161
	Kelor+IFA	26	73.97682639	28.160810127	5.522789244
Berat Badan Lahir	IFA	30	2993.67	492.296	89.880
	Kelor+IFA	26	3042.31	411.449	80.692
Panjang Badan Lahir	IFA	30	48.23	2.329	.425
	Kelor+IFA	26	48.62	1.675	.329
Depression Anxiety Stress Scales	IFA	30	11.23	6.447	1.177
	Kelor+IFA	26	10.38	6.765	1.327

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
MDA	Equal variances assumed	3.212	.079	1.092	54	.280	1.672113562	1.531054583	-1.397466061	4.741693184
	Equal variances not assumed			1.017	25.382	.319	1.672113562	1.644856672	-1.712949655	5.057176778
Kortisol	Equal variances assumed	.545	.464	-.437	54	.664	-3.415948931	7.815368563	-19.084819493	12.252921631
	Equal variances not assumed			-.439	53.637	.662	-3.415948931	7.779366996	-19.015060197	12.183162334
Berat Badan Lahir	Equal variances assumed	.285	.596	-.398	54	.693	-48.641	122.357	-293.953	196.671
	Equal variances not assumed			-.403	53.940	.689	-48.641	120.788	-290.812	193.530
Panjang Badan Lahir	Equal variances assumed	.724	.399	-.695	54	.490	-.382	.550	-1.485	.721
	Equal variances not assumed			-.711	52.323	.480	-.382	.537	-1.460	.696
Depression Anxiety Stress Scales	Equal variances assumed	.116	.734	.480	54	.633	.849	1.767	-2.695	4.392
	Equal variances not assumed			.479	52.046	.634	.849	1.774	-2.710	4.408

T-Test**Notes**

Output Created		27-DEC-2022 11:10:05
Comments		
Input	Data Active Dataset Filter Weight Split File N of Rows in Working Data File	F:\Dr. RAHMA\Untitled1.sav DataSet1 <none> <none> <none> 56
Missing Value Handling	Definition of Missing Cases Used	User defined missing values are treated as missing. Statistics for each analysis are based on the cases with no missing or out-of-range data for any variable in the analysis. T-TEST GROUPS=Kat_BBL(1 2) /MISSING=ANALYSIS /VARIABLES=MDA Kortisol DASS42 /CRITERIA=CI(.95).
Syntax		
Resources	Processor Time Elapsed Time	00:00:00,02 00:00:00,03

[DataSet1] F:\Dr. RAHMA\Untitled1.sav

Group Statistics

	Kategori BBL	N	Mean	Std. Deviation	Std. Error Mean
MDA(nmol/ml)	<2500	4	49.46355418	.644910844	.322455422
	>=2500	52	48.40290717	5.935332584	.823082537
Kortisol (ng/ml)	<2500	4	80.92747722	27.998307498	13.999153749
	>=2500	52	76.66372887	28.471165151	3.948240224
Depression Anxiety	<2500	4	11.25	6.946	3.473
Stress Scales	>=2500	52	10.81	6.589	.914

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
MDA(nmol/ml)	Equal variances assumed	.193	.663	.354	54	.725	1.060647015	2.993962566	-4.941886522	7.063180553
	Equal variances not assumed			1.200	48.453	.236	1.060647015	.883992286	-.716309348	2.837603379
Kortisol (ng/ml)	Equal variances assumed	.154	.697	.289	54	.774	4.263748352	14.759438434	-25.327144071	33.854640774
	Equal variances not assumed			.293	3.495	.786	4.263748352	14.545270935	-38.529473707	47.056970410
Depression Anxiety	Equal variances assumed	.034	.853	.129	54	.898	.442	3.429	-6.433	7.318
	Equal variances not assumed			.123	3.429	.909	.442	3.591	-10.219	11.104

T-Test**Notes**

Output Created		27-DEC-2022 12:15:06
Comments		
Input	Data Active Dataset Filter Weight Split File N of Rows in Working Data File	F:\Dr. RAHMA\Untitled1.sav DataSet1 <none> <none> <none> 56
Missing Value Handling	Definition of Missing Cases Used	User defined missing values are treated as missing. Statistics for each analysis are based on the cases with no missing or out-of-range data for any variable in the analysis. T-TEST GROUPS=Kat_PBL(1 2) /MISSING=ANALYSIS /VARIABLES=MDA Kortisol DASS42 /CRITERIA=C1(.95).
Syntax		
Resources	Processor Time Elapsed Time	00:00:00,00 00:00:00,02

[DataSet1] F:\Dr. RAHMA\Untitled1.sav

Group Statistics

	Kategori PBL	N	Mean	Std. Deviation	Std. Error Mean
MDA(nmol/ml)	<48	13	49.13714670	.612053851	.169753196
	?48	43	48.27959261	6.528740194	.995623546
Kortisol (ng/ml)	<48	13	68.68914565	25.699078085	7.127641828
	?48	43	79.47127713	28.732937054	4.381731822
Depression Anxiety Stress Scales	<48	13	11.77	6.534	1.812
	?48	43	10.56	6.606	1.007

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
MDA(nmol/ml)	Equal variances assumed	.771	.384	.470	54	.640	.857554086	1.824693151	-2.800735420	4.515843591
	Equal variances not assumed			.849	44.346	.400	.857554086	1.009991283	-1.177500855	2.892609026
Kortisol (ng/ml)	Equal variances assumed	.340	.562	-1.213	54	.230	-10.782131475	8.889855708	-28.605219059	7.040956110
	Equal variances not assumed			-1.289	21.891	.211	-10.782131475	8.366770691	-28.138777525	6.574514575
Depression Anxiety Stress Scales	Equal variances assumed	.143	.706	.581	54	.564	1.211	2.086	-2.971	5.393
	Equal variances not assumed			.584	20.015	.566	1.211	2.073	-3.114	5.536

ANALISIS RISIKO RELATIF (RR)**Kode Kapsul * Kadar MDA****Crosstab**

			Kadar MDA		Total
			Tinggi ($\geq 49,1$)	Rendah ($< 49,1$)	
Kode Kapsul	IFA+Kelor	Count	9	17	26
		% within Kode Kapsul	34.6%	65.4%	100.0%
	IFA	Count	15	15	30
		% within Kode Kapsul	50.0%	50.0%	100.0%
Total	Count	24	32	56	
	% within Kode Kapsul	42.9%	57.1%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.346 ^a	1	.246		
Continuity Correction ^b	.791	1	.374		
Likelihood Ratio	1.355	1	.244		
Fisher's Exact Test				.288	.187
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.14.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode Kapsul (IFA+Kelor / IFA)	.529	.180	1.558
For cohort Kadar MDA = Tinggi ($\geq 49,1$)	.692	.366	1.310
For cohort Kadar MDA = Rendah ($< 49,1$)	1.308	.830	2.059
N of Valid Cases	56		

Kode kapsul 1 * Kadar MDA 1

Crosstab

			Kadar MDA 1		Total
			Tinggi	Rendah	
Kode kapsul 1	IFA	Count	15	15	30
		% within Kode kapsul 1	50.0%	50.0%	100.0%
	IFA+Kelor	Count	9	17	26
		% within Kode kapsul 1	34.6%	65.4%	100.0%
Total	Count	24	32	56	
	% within Kode kapsul 1	42.9%	57.1%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.346 ^a	1	.246		
Continuity Correction ^b	.791	1	.374		
Likelihood Ratio	1.355	1	.244		
Fisher's Exact Test				.288	.187
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.14.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode kapsul 1 (IFA / IFA+Kelor)	1.889	.642	5.559
For cohort Kadar MDA 1 = Tinggi	1.444	.763	2.734
For cohort Kadar MDA 1 = Rendah	.765	.486	1.204
N of Valid Cases	56		

Kode Kapsul * Kadar Kortisol

Crosstab

		Kadar Kortisol		Total
		Tinggi (≥ 87)	Rendah (< 87)	
Kode Kapsul	IFA+Kelor	Count 11	Count 15	Count 26
		% within Kode Kapsul 42.3%	% within Kode Kapsul 57.7%	% within Kode Kapsul 100.0%
Kode Kapsul	IFA	Count 19	Count 11	Count 30
		% within Kode Kapsul 63.3%	% within Kode Kapsul 36.7%	% within Kode Kapsul 100.0%
Total		Count 30	Count 26	Count 56
		% within Kode Kapsul 53.6%	% within Kode Kapsul 46.4%	% within Kode Kapsul 100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.476 ^a	1	.116		
Continuity Correction ^b	1.702	1	.192		
Likelihood Ratio	2.491	1	.114		
Fisher's Exact Test				.179	.096
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.07.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode Kapsul (IFA+Kelor / IFA)	.425	.145	1.245
For cohort Kadar Kortisol = Tinggi (≥ 87)	.668	.395	1.129
For cohort Kadar Kortisol = Rendah (< 87)	1.573	.886	2.794
N of Valid Cases	56		

Kode kapsul 1 * Kadar Kortisol

Crosstab

			Kadar Kortisol		Total
			Tinggi	Rendah	
Kode kapsul 1	IFA	Count	19	11	30
		% within Kode kapsul 1	63.3%	36.7%	100.0%
	IFA+Kelor	Count	11	15	26
		% within Kode kapsul 1	42.3%	57.7%	100.0%
Total	Count	30	26	56	
	% within Kode kapsul 1	53.6%	46.4%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.476 ^a	1	.116		
Continuity Correction ^b	1.702	1	.192		
Likelihood Ratio	2.491	1	.114		
Fisher's Exact Test				.179	.096
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.07.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode kapsul 1 (IFA / IFA+Kelor)	2.355	.803	6.905
For cohort Kadar Kortisol = Tinggi	1.497	.886	2.531
For cohort Kadar Kortisol = Rendah	.636	.358	1.128
N of Valid Cases	56		

Kode Kapsul * DASS

Crosstab

		DASS		Total	
		Tinggi (≥ 10)	Rendah (< 10)		
Kode Kapsul	IFA+Kelor	Count	14	12	26
		% within Kode Kapsul	53.8%	46.2%	100.0%
IFA		Count	16	14	30
		% within Kode Kapsul	53.3%	46.7%	100.0%
Total		Count	30	26	56
		% within Kode Kapsul	53.6%	46.4%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.001 ^a	1	.969		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.001	1	.969		
Fisher's Exact Test				1.000	.591
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.07.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode Kapsul (IFA+Kelor / IFA)	1.021	.356	2.926
For cohort DASS = Tinggi (≥ 10)	1.010	.619	1.646
For cohort DASS = Rendah (< 10)	.989	.562	1.739
N of Valid Cases	56		

Kode Kapsul * Berat Badan Lahir

Crosstab

		Berat Badan Lahir		Total	
		<2500	≥2500		
Kode Kapsul	IFA+Kelor	Count	0	26	26
		% within Kode Kapsul	0.0%	100.0%	100.0%
Kode Kapsul	IFA	Count	4	26	30
		% within Kode Kapsul	13.3%	86.7%	100.0%
Total		Count	4	52	56
		% within Kode Kapsul	7.1%	92.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	3.733 ^a	1	.053		
Continuity Correction ^b	1.994	1	.158		
Likelihood Ratio	5.259	1	.022		
Fisher's Exact Test				.115	.075
N of Valid Cases	56				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
For cohort Berat Badan Lahir = ≥2500	1.154	1.003	1.328
N of Valid Cases	56		

Kode Kapsul * Panjang Badan Lahir

Crosstab

		Panjang Badan Lahir		Total	
		<48 cm	≥48 cm		
Kode Kapsul	IFA+Kelor	Count	6	20	26
		% within Kode Kapsul	23.1%	76.9%	100.0%
	IFA	Count	7	23	30
		% within Kode Kapsul	23.3%	76.7%	100.0%
Total	Count	13	43	56	
	% within Kode Kapsul	23.2%	76.8%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.001 ^a	1	.982		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.001	1	.982		
Fisher's Exact Test				1.000	.617
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.04.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kode Kapsul (IFA+Kelor / IFA)	.986	.284	3.421
For cohort Panjang Badan Lahir = <48 cm	.989	.380	2.572
For cohort Panjang Badan Lahir = ≥48 cm	1.003	.752	1.339
N of Valid Cases	56		

MDA * Berat Badan Lahir

		Berat Badan Lahir		Total	
		<2500gr	>=2500		
MDA	Tinggi >= 49,1	Count	3	21	24
		% within MDA	12.5%	87.5%	100.0%
	Rendah <49,1	Count	1	31	32
		% within MDA	3.1%	96.9%	100.0%
Total		Count	4	52	56
		% within MDA	7.1%	92.9%	100.0%

Chi-Square Tests

	Value	Df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.817 ^a	1	.178		
Continuity Correction ^b	.679	1	.410		
Likelihood Ratio	1.835	1	.176		
Fisher's Exact Test				.303	.205
N of Valid Cases	56				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.71.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for MDA (Tinggi >= 49,1 / Rendah <49,1)	4.429	.431	45.516
For cohort Berat Badan Lahir = <2500gr	4.000	.443	36.115
For cohort Berat Badan Lahir = >=2500	.903	.767	1.064
N of Valid Cases	56		

Kadar Kortisol * Berat Badan Lahir

Crosstab

			Berat Badan Lahir		Total
			<2500gr	>=2500	
Kadar Kortisol	Tinggi .>=87	Count	3	27	30
		% within Kadar Kortisol	10.0%	90.0%	100.0%
	Rendah<87	Count	1	25	26
		% within Kadar Kortisol	3.8%	96.2%	100.0%
Total	Count	4	52	56	
	% within Kadar Kortisol	7.1%	92.9%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.795 ^a	1	.373		
Continuity Correction ^b	.138	1	.710		
Likelihood Ratio	.837	1	.360		
Fisher's Exact Test				.615	.362
N of Valid Cases	56				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kadar Kortisol (Tinggi .>=87 / Rendah<87)	2.778	.271	28.482
For cohort Berat Badan Lahir = <2500gr	2.600	.288	23.498
For cohort Berat Badan Lahir = >=2500	.936	.812	1.079
N of Valid Cases	56		

DASS * Berat Badan Lahir**Crosstab**

		Berat Badan Lahir		Total	
		<2500gr	>=2500		
DASS	Tinggi >=10	Count	2	28	30
		% within DASS	6.7%	93.3%	100.0%
	<10	Count	2	24	26
		% within DASS	7.7%	92.3%	100.0%
Total		Count	4	52	56
		% within DASS	7.1%	92.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.022 ^a	1	.882		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.022	1	.882		
Fisher's Exact Test				1.000	.638
N of Valid Cases	56				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for DASS (Tinggi >=10 / <10)	.857	.112	6.555
For cohort Berat Badan Lahir = <2500gr	.867	.131	5.727
For cohort Berat Badan Lahir = >=2500	1.011	.873	1.171
N of Valid Cases	56		

MDA * Panjang Badan Lahir

Crosstab

		Panjang Badan Lahir		Total	
		<48 cm	>=48 cm		
MDA	≥49,1 cm	Count	9	15	24
		% within MDA	37.5%	62.5%	100.0%
	<49,1	Count	4	28	32
		% within MDA	12.5%	87.5%	100.0%
Total	Count	13	43	56	
	% within MDA	23.2%	76.8%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.809 ^a	1	.028		
Continuity Correction ^b	3.508	1	.061		
Likelihood Ratio	4.819	1	.028		
Fisher's Exact Test				.053	.031
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.57.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for MDA (≥49,1 cm / <49,1)	4.200	1.106	15.950
For cohort Panjang Badan Lahir = <48 cm	3.000	1.048	8.592
For cohort Panjang Badan Lahir = ≥48 cm	.714	.510	1.000
N of Valid Cases	56		

Kadar Kortisol * Panjang Badan Lahir

Crosstab

			Panjang Badan Lahir		Total
			<48 cm	>=48 cm	
Kadar Kortisol	Tinggal >=87	Count	5	25	30
		% within Kadar Kortisol	16.7%	83.3%	100.0%
	Rendah <87	Count	8	18	26
		% within Kadar Kortisol	30.8%	69.2%	100.0%
Total	Count	13	43	56	
	% within Kadar Kortisol	23.2%	76.8%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.554 ^a	1	.213		
Continuity Correction ^b	.864	1	.353		
Likelihood Ratio	1.557	1	.212		
Fisher's Exact Test				.342	.176
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.04.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Kadar Kortisol (Tinggal >=87 / Rendah <87)	.450	.126	1.604
For cohort Panjang Badan Lahir = <48 cm	.542	.202	1.452
For cohort Panjang Badan Lahir = >=48 cm	1.204	.890	1.628
N of Valid Cases	56		

DASS * Panjang Badan Lahir

Crosstab

		Panjang Badan Lahir		Total	
		<48 cm	>=48 cm		
DASS	Tinggi >=10	Count	7	23	30
		% within DASS	23.3%	76.7%	100.0%
	rendah <10	Count	6	20	26
		% within DASS	23.1%	76.9%	100.0%
Total		Count	13	43	56
		% within DASS	23.2%	76.8%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.001 ^a	1	.982		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.001	1	.982		
Fisher's Exact Test				1.000	.617
N of Valid Cases	56				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.04.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for DASS (Tinggi >=10 / rendah <10)	1.014	.292	3.521
For cohort Panjang Badan Lahir = <48 cm	1.011	.389	2.629
For cohort Panjang Badan Lahir = >=48 cm	.997	.747	1.330
N of Valid Cases	56		

LAMPIRAN 7

DOKUMENTASI PENELITIAN



